Antibody targeting of ovarian cancer: recombinant single-chain fragments and the role of internalization
Among the factors that have hindered development of antibody based therapy are the heterogeneity of tumor antigen expression, the Hmited penetration of bulk tumor masses by macromolecules, cross reactivity between tumor and normal host antigens and unfavourable patterns of antibody internalization . With greater understanding of these obstacles and the ability to engineer changes within the antibody molecule itself, there has been renewed enthusiasm for development and evaluation of immunoconjugates. Improved molecular and functional characterization of tumor antigens has influenced the design of targeting strategies and contributed to the analysis of normal tissue distribution and potential for host toxicity. Furthermore, the choice of specific radionuclide, toxin or drug conjugate has been influenced by increased knowledge of antibody internalization and processing pathways. Thus, a new generation of reagents is being prepared for clinical trial that takes full advantage of past experiences and recent advances in molecular and cellular biology.
KeywordsOvarian Cancer Epidermal Growth Factor Receptor SKBR3 Cell Flow Cytometric Assay Antibody Target
Unable to display preview. Download preview PDF.
- 12.Bookman, M.A. (1992) Immunotoxin therapy in ovarian cancer. In Ovarian Cancer 2: Biology, Diagnosis and Management, (eds P. Mason, F. Sharp and W. Creasman), Chapman & Hall, London, pp. 153–60.Google Scholar
- 15.Skerra, A. and Pluckthun, A. (1988) Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science, 240,1038–41.Google Scholar
- 20.Tai, M.-S., Mudgett-Hunter, M., Levinson, D. et al. (1990) A bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain Fv. Biochemistry, 29, 8024–30. 24.Google Scholar
- 23.McCartney, J.E., Tai, M.-S., Opperman, H. et al. (1993) Refolding of single-chain Fv with C-terminal cystein (sFv’); formation of disulfide-bonded homodimers of anti-c-erbB2 and anti-digoxin sFv’. Miami Short Reports, 3, 91.Google Scholar